These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 25139840)

  • 1. Pharmacokinetics of caspofungin in ICU patients.
    Muilwijk EW; Schouten JA; van Leeuwen HJ; van Zanten AR; de Lange DW; Colbers A; Verweij PE; Burger DM; Pickkers P; Brüggemann RJ
    J Antimicrob Chemother; 2014 Dec; 69(12):3294-9. PubMed ID: 25139840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Altered Micafungin Pharmacokinetics in Intensive Care Unit Patients.
    Lempers VJ; Schouten JA; Hunfeld NG; Colbers A; van Leeuwen HJ; Burger DM; Verweij PE; Pickkers P; Brüggemann RJ
    Antimicrob Agents Chemother; 2015 Aug; 59(8):4403-9. PubMed ID: 25963988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low Caspofungin Exposure in Patients in Intensive Care Units.
    van der Elst KC; Veringa A; Zijlstra JG; Beishuizen A; Klont R; Brummelhuis-Visser P; Uges DR; Touw DJ; Kosterink JG; van der Werf TS; Alffenaar JC
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27855112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of Anidulafungin in Critically Ill Intensive Care Unit Patients with Suspected or Proven Invasive Fungal Infections.
    Brüggemann RJ; Middel-Baars V; de Lange DW; Colbers A; Girbes AR; Pickkers P; Swart EL
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study.
    Sinnollareddy MG; Roberts JA; Lipman J; Akova M; Bassetti M; De Waele JJ; Kaukonen KM; Koulenti D; Martin C; Montravers P; Rello J; Rhodes A; Starr T; Wallis SC; Dimopoulos G;
    Crit Care; 2015 Feb; 19(1):33. PubMed ID: 25888060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Caspofungin Population Pharmacokinetics in Critically Ill Patients Undergoing Continuous Veno-Venous Haemofiltration or Haemodiafiltration.
    Roger C; Wallis SC; Muller L; Saissi G; Lipman J; Brüggemann RJ; Lefrant JY; Roberts JA
    Clin Pharmacokinet; 2017 Sep; 56(9):1057-1068. PubMed ID: 28035589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic/pharmacodynamics variability of echinocandins in critically ill patients: A systematic review and meta-analysis.
    Liu X; Liu D; Pan Y; Li Y
    J Clin Pharm Ther; 2020 Dec; 45(6):1207-1217. PubMed ID: 32672361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of a transjugular intrahepatic portosystemic shunt on the pharmacokinetics of caspofungin in a critically ill patient.
    Spriet I; Meyfroidt G; Maleux G; Verslype C; Willems L
    Pharmacology; 2012; 90(5-6):247-50. PubMed ID: 23007631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics and pharmacodynamics of caspofungin in pediatric patients.
    Li CC; Sun P; Dong Y; Bi S; Desai R; Dockendorf MF; Kartsonis NA; Ngai AL; Bradshaw S; Stone JA
    Antimicrob Agents Chemother; 2011 May; 55(5):2098-105. PubMed ID: 21300834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma concentrations of caspofungin at two different dosage regimens in a patient with hepatic dysfunction.
    van der Elst KC; Brüggemann RJ; Rodgers MG; Alffenaar JW
    Transpl Infect Dis; 2012 Aug; 14(4):440-3. PubMed ID: 22316392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics of escalating doses of caspofungin in a phase II study of patients with invasive aspergillosis.
    Würthwein G; Cornely OA; Trame MN; Vehreschild JJ; Vehreschild MJ; Farowski F; Müller C; Boos J; Hempel G; Hallek M; Groll AH
    Antimicrob Agents Chemother; 2013 Apr; 57(4):1664-71. PubMed ID: 23335740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II dose escalation study of caspofungin for invasive Aspergillosis.
    Cornely OA; Vehreschild JJ; Vehreschild MJ; Würthwein G; Arenz D; Schwartz S; Heussel CP; Silling G; Mahne M; Franklin J; Harnischmacher U; Wilkens A; Farowski F; Karthaus M; Lehrnbecher T; Ullmann AJ; Hallek M; Groll AH
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5798-803. PubMed ID: 21911573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and pharmacokinetics of higher doses of caspofungin in healthy adult participants.
    Migoya EM; Mistry GC; Stone JA; Comisar W; Sun P; Norcross A; Bi S; Winchell GA; Ghosh K; Uemera N; Deutsch PJ; Wagner JA
    J Clin Pharmacol; 2011 Feb; 51(2):202-11. PubMed ID: 20679501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative pharmacokinetics of the three echinocandins in ICU patients.
    Mainas E; Apostolopoulou O; Siopi M; Apostolidi S; Neroutsos E; Mirfendereski H; Marchand S; Couet W; Dokoumetzidis A; Valsami G; Sambatakou H; Dimopoulos G; Meletiadis J
    J Antimicrob Chemother; 2020 Oct; 75(10):2969-2976. PubMed ID: 32696036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age.
    Sáez-Llorens X; Macias M; Maiya P; Pineros J; Jafri HS; Chatterjee A; Ruiz G; Raghavan J; Bradshaw SK; Kartsonis NA; Sun P; Strohmaier KM; Fallon M; Bi S; Stone JA; Chow JW
    Antimicrob Agents Chemother; 2009 Mar; 53(3):869-75. PubMed ID: 19075070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Invasive candidiasis treated in the intensive care unit: observations from a randomized clinical trial.
    DiNubile MJ; Lupinacci RJ; Strohmaier KM; Sable CA; Kartsonis NA
    J Crit Care; 2007 Sep; 22(3):237-44. PubMed ID: 17869975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose Reduction of Caspofungin in Intensive Care Unit Patients with Child Pugh B Will Result in Suboptimal Exposure.
    Martial LC; Brüggemann RJ; Schouten JA; van Leeuwen HJ; van Zanten AR; de Lange DW; Muilwijk EW; Verweij PE; Burger DM; Aarnoutse RE; Pickkers P; Dorlo TP
    Clin Pharmacokinet; 2016 Jun; 55(6):723-33. PubMed ID: 26649870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of caspofungin in a critically ill patient with liver cirrhosis.
    Spriet I; Meersseman W; Annaert P; de Hoon J; Willems L
    Eur J Clin Pharmacol; 2011 Jul; 67(7):753-5. PubMed ID: 21638033
    [No Abstract]   [Full Text] [Related]  

  • 19. Micafungin pharmacokinetic/pharmacodynamic adequacy for the treatment of invasive candidiasis in critically ill patients on continuous venovenous haemofiltration.
    Maseda E; Grau S; Villagran MJ; Hernandez-Gancedo C; Lopez-Tofiño A; Roberts JA; Aguilar L; Luque S; Sevillano D; Gimenez MJ; Gilsanz F
    J Antimicrob Chemother; 2014 Jun; 69(6):1624-32. PubMed ID: 24505092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of caspofungin acetate to guide optimal dosing in cats.
    Leshinsky J; McLachlan A; Foster DJR; Norris R; Barrs VR
    PLoS One; 2017; 12(6):e0178783. PubMed ID: 28575121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.